NCT04577521View on ClinicalTrials.gov

The Safety and Efficacy of Single IA-HA Injection in Patients With Knee Osteoarthritis: A Prospective Study

CompletedOBSERVATIONAL
Enrollment

67

Participants

Timeline

Start Date

March 4, 2019

Primary Completion Date

January 29, 2020

Study Completion Date

January 29, 2020

Conditions
Gonarthrosis
Interventions
DEVICE

BioVisc Ortho Single

BioVisc Ortho Single consisted of a prefilled syringe containing 90 mg/3 mL of IA-HA and is an injectable-grade HA from a biofermentation origin. Biovisc ortho single prefilled syringes are intended for single-use only, and the entire content of the syringe was injected into the target joint.

Trial Locations (1)

34732

İstanbul Medeniyet University, Istanbul

All Listed Sponsors
lead

Goztepe Training and Research Hospital

OTHER

NCT04577521 - The Safety and Efficacy of Single IA-HA Injection in Patients With Knee Osteoarthritis: A Prospective Study | Biotech Hunter | Biotech Hunter